Concepts (102)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 8 | 2023 | 169 | 2.230 |
Why?
|
| Hodgkin Disease | 2 | 2024 | 293 | 0.680 |
Why?
|
| Vitamin D Deficiency | 1 | 2020 | 70 | 0.640 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 712 | 0.440 |
Why?
|
| HIV Infections | 3 | 2024 | 1864 | 0.420 |
Why?
|
| Frailty | 2 | 2024 | 97 | 0.390 |
Why?
|
| Veterans | 5 | 2024 | 1725 | 0.350 |
Why?
|
| Wearable Electronic Devices | 2 | 2024 | 101 | 0.340 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2021 | 128 | 0.320 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2018 | 101 | 0.280 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2018 | 77 | 0.270 |
Why?
|
| Neoplasms | 4 | 2024 | 2750 | 0.260 |
Why?
|
| Dexamethasone | 3 | 2023 | 272 | 0.250 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 1675 | 0.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 1230 | 0.230 |
Why?
|
| Dyspnea | 1 | 2024 | 149 | 0.210 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 74 | 0.210 |
Why?
|
| Multiple Chronic Conditions | 1 | 2021 | 14 | 0.190 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 272 | 0.170 |
Why?
|
| Chromatin | 1 | 2022 | 552 | 0.160 |
Why?
|
| Treatment Outcome | 6 | 2024 | 12087 | 0.160 |
Why?
|
| Humans | 22 | 2024 | 122996 | 0.150 |
Why?
|
| Aged | 11 | 2024 | 19035 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 532 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2019 | 220 | 0.140 |
Why?
|
| Paraproteinemias | 1 | 2016 | 16 | 0.130 |
Why?
|
| Motor Activity | 1 | 2019 | 520 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 1114 | 0.120 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2016 | 137 | 0.120 |
Why?
|
| Amyloidosis | 1 | 2015 | 66 | 0.110 |
Why?
|
| Hospitalization | 1 | 2022 | 1732 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 113 | 0.110 |
Why?
|
| Azacitidine | 1 | 2011 | 54 | 0.090 |
Why?
|
| Urologic Neoplasms | 1 | 2011 | 39 | 0.090 |
Why?
|
| United States | 5 | 2024 | 10595 | 0.090 |
Why?
|
| Cardiomyopathies | 1 | 2015 | 481 | 0.090 |
Why?
|
| Bortezomib | 2 | 2023 | 73 | 0.080 |
Why?
|
| Myocardium | 1 | 2015 | 982 | 0.080 |
Why?
|
| Gait | 2 | 2021 | 145 | 0.080 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2007 | 18 | 0.070 |
Why?
|
| Phosphatidylserines | 1 | 2007 | 47 | 0.070 |
Why?
|
| Adult | 4 | 2024 | 28980 | 0.070 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2023 | 650 | 0.070 |
Why?
|
| Middle Aged | 6 | 2024 | 25931 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 6359 | 0.070 |
Why?
|
| Phagocytosis | 1 | 2007 | 170 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2007 | 321 | 0.070 |
Why?
|
| Male | 7 | 2024 | 59901 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3510 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 515 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2011 | 991 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2023 | 1088 | 0.060 |
Why?
|
| Anemia, Sickle Cell | 1 | 2007 | 334 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2024 | 104 | 0.050 |
Why?
|
| Proteasome Inhibitors | 1 | 2022 | 60 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2023 | 94 | 0.050 |
Why?
|
| Genes, myc | 1 | 2022 | 98 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2022 | 262 | 0.050 |
Why?
|
| Multimorbidity | 1 | 2021 | 18 | 0.050 |
Why?
|
| Rural Population | 1 | 2023 | 249 | 0.050 |
Why?
|
| Survival Rate | 2 | 2016 | 1993 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 501 | 0.040 |
Why?
|
| Fear | 1 | 2021 | 201 | 0.040 |
Why?
|
| Accidental Falls | 1 | 2021 | 106 | 0.040 |
Why?
|
| Exercise | 1 | 2024 | 809 | 0.040 |
Why?
|
| Postural Balance | 1 | 2019 | 124 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2022 | 1002 | 0.040 |
Why?
|
| Comorbidity | 1 | 2021 | 1498 | 0.030 |
Why?
|
| Female | 5 | 2024 | 65309 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2024 | 15930 | 0.030 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2015 | 10 | 0.030 |
Why?
|
| Autografts | 1 | 2015 | 26 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2015 | 48 | 0.030 |
Why?
|
| Biomarkers | 1 | 2024 | 2940 | 0.030 |
Why?
|
| Pyrazines | 1 | 2015 | 73 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 230 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2015 | 146 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 590 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2015 | 238 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2015 | 184 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 860 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2015 | 417 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 1303 | 0.030 |
Why?
|
| Prognosis | 1 | 2021 | 4490 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 4705 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 1215 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 614 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 3259 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1684 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 2837 | 0.020 |
Why?
|
| Cardiac Catheterization | 1 | 2015 | 634 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1870 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2015 | 961 | 0.020 |
Why?
|
| Echocardiography | 1 | 2015 | 1069 | 0.020 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2007 | 15 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2007 | 206 | 0.020 |
Why?
|
| Cattle | 1 | 2007 | 559 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 815 | 0.020 |
Why?
|
| Protein Binding | 1 | 2007 | 1741 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 1015 | 0.010 |
Why?
|
| Mice | 1 | 2007 | 17469 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 33693 | 0.000 |
Why?
|